Rescape Innovation Ltd, an immersive tech start-up created by the Orchard Media and Events Group, won the ‘Most Innovative’ award for VR Distraction Therapy at this years Healthcare and Life Sciences Awards run by Corporate LiveWire. During the awards process over 90,000 Healthcare & Medical professionals were asked to nominate associations, companies & individuals based on their achievements over the previous 12 months. Information was submitted on each nominee and Corporate LiveWire’s independent judging panel decided upon the most deserving teams, companies and individuals to walk away with one of these prestigious accolades.
Distraction therapy is being used more and more frequently as a useful adjunct to current treatment supporting patients with a range of illnesses such as cancer, dementia, Alzheimer’s and mental illness, relieving pain, anxiety and stress. DRVR is being utilised in many different healthcare institutions such as hospitals, hospices and care homes and many different departments such as ITU, palliative care, accident and emergency, inpatients and outpatients.
Rescape Innovation Ltd develops immersive technologies to support patient care. We specialise in virtual reality distraction therapy and utilising immersive technologies to support communication, pain management, anxiety/stress management and the patient experience. Rescape prides itself in making technology accessible to all by producing cost-effective solutions that are simple and straightforward to implement and suitable for a healthcare environment.
Glenn Hapgood, Head of Product & Innovation, said:
“Virtual reality can play a big part in helping patients with their treatments. The benefit
the industry is that it’s accessible and cost-effective while there are multiple benefits for the patient. VR is non-intrusive and can be used by anyone with no requirement for a prescription. Treatments and procedures can be very uncomfortable and to offer patients relief from the pain and anxiety and to virtually transport them away from the hospital environment is very rewarding. So far we have over 400 use cases and the average reduction in pain is currently 50.3% and the average reduction in anxiety/stress currently sits at 56.0%. The reaction to DRVR and DRVR+ has been outstanding with clinicians immediately recognising the benefits of our product.”
Email: [email protected]
Tel: 02920 100919